Author

F. Gibson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:chromatin & epigenetic regulation· 1 Assay:CRISPR screen· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

A. Hanly· 1 shared A. Labadorf· 1 shared A. R. Bassett· 1 shared A. Xiao· 1 shared C. Dincer· 1 shared C. Hardy· 1 shared C. M. Cattaneo· 1 shared E. Goncalves· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Hanly

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Base editing screens map mutations affecting IFNγ signalling in cancer

M. A. Coelho, E. Karakoc, S. G. Bhosle, E. Goncalves, T. Burgold, S. Cooper, C. M. Cattaneo, V. Veninga, S. Consonni, C. Dincer, S. F. Vieira, F. Gibson, S. Barthorpe, C. Hardy, J. Rein, , M. J. Garnett

This study uses base editing to identify mutations affecting IFNγ signalling in cancer, revealing loss- and gain-of-function variants with clinical relevance.

bioRxiv · Mar 29, 2022 · PreprintCancer Biology

The CoREST Repressor Complex Mediates Phenotype Switching and Therapy Resistance in Melanoma

M. Wu, A. Hanly, F. Gibson, K. H. Kuang, J. Kalin, S. Nocco, M. Collard, M. W. Cole, A. Xiao, F. Agus, A. Labadorf, P. A. Cole, R. M. Alani

This study identifies the CoREST repressor complex as a mediator of melanoma phenotype switching and therapy resistance, showing that its inhibitor corin can reverse resistance to BRAF inhibitors.

bioRxiv · Sep 30, 2020Cancer Biology